MarginsXMarginsX
Home › Markets › Health Care › NAMS

NewAmsterdam Pharma Company N.V. (NAMS)

NAMS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.46
-3.38% on the day
Market cap
$2.3B
Mid cap
Revenue · 2025
$22.5M
-50.6% on 2024
Net income · 2025
-$203.8M
-905.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNAMS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNetherlands
IPO yearNot reported by the screener
SEC CIK0001936258
SEC industry codePharmaceutical Preparations
Incorporated inNetherlands

Financials · 2025

LineValue
Revenue$22.5M
Net income-$203.8M
Operating income-$225.7M
Net margin-905.7%
Operating margin-1002.9%
Revenue growth-50.6%
Cash$490.0M
Total assets$769.3M
P/E (computed)Net income was not positive
P/S (computed)103.7×

Warning signs

Cash runway
33.7 months
$423.1M cash at September 30, 2026
Share count, 1 year
+5.8%
2025-10-31 to 2026-11-02 · +34.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$61.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$423.1M cash; operating cash flow -$37.6M a quarter.Report 2026-09-30
Shares outstanding119,929,998 (2026-11-02); 113,390,804 a year earlier; 89,266,673 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Accountants B.V., Eindhoven, NetherlandsPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $227K, sold $62.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$19.2M-$17.4M-$39.8M$423.1MNo debt tags$25.9M10-Q 2026-11-04
Q2 2026
2026-06-30
$3.7M-$64.1M-$39.2M$424.2MNo debt tags$7.1M10-Q 2026-08-05
Q1 2026
2026-03-31
$3.0M-$48.4M-$30.6M$457.6MNo debt tags$22.6M10-Q 2026-05-07
Q4 2025
2025-12-31
$32K-$74.9M-$40.9M$490.0MNo debt tags$22.5M10-K 2026-02-18
Q3 2025
2025-09-30
$348K-$72.0M-$32.8M$538.4MNo debt tags$35.2M10-Q 2026-11-04
Q2 2025
2025-06-30
$19.1M-$17.4M-$37.7M$563.9MNo debt tags$64.0M10-Q 2026-08-05
Q1 2025
2025-03-31
$3.0M-$39.5M-$36.5M$748.4MNo debt tags$47.1M10-Q 2026-05-07
Q4 2024
2024-12-31
$12.8M-$92.2M-$37.5M$771.7MNo debt tags$45.6M10-K 2026-02-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-03-10
Latest annual report10-K2026-02-18
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEF 14A2026-05-06

Source: SEC EDGAR submissions feed, 417 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.6%
1 month-0.2%
3 months-24.5%
Year to date-42.6%
1 year-44.7%
From 52-week high-51.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
NAMSWNewAmsterdam Pharma Company N.V. Warrant$9.49

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B
PHVSPharvaris N.V.$32.44-2.76%$2.3B
PRGOPerrigo Company plc$16.18-0.37%$2.2B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
HCMHUTCHMED (China) Limited$14.73-1.14%$2.6B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier